Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients.

Fiche publication


Date publication

janvier 2022

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr FEIN Francine, Dr VERNEREY Dewi, Dr VIENOT Angélique, Dr KIM Stephano, Mme HENRIQUES Julie


Tous les auteurs :
Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S

Résumé

Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma (GEA). However, the effect of taxanes combined with platin-5FU + trastuzumab (PFT) is understudied.

Mots clés

HER2, gastric carcinoma, metastatic, survival, taxanes, trastuzumab

Référence

Front Oncol. 2022 ;12:763926